Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
about
Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer.Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.Bone marrow tolerance during postoperative chemotherapy in colorectal carcinomas.Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.Chemoradiotherapy and concurrent radiofrequency thermal therapy to treat primary rectal cancer and prediction of treatment responses.Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis.Oral versus intravenous fluoropyrimidines for colorectal cancer.[Inclusion of oxaliplatin in the multimodal treatment of locally advanced rectal cancer].Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis.Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization.Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study.Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064).The Role of Oxaliplatin in Chemoradiotherapy for Rectal Cancer.Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option?Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer.Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer.Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer.Organ preservation in rectal cancer - Challenges and future strategies.Neoadjuvant chemoradiotherapy of the rectal carcinoma - The correlation between the findings on the restaging multiparametric 3T MRI scanning and the surgical findings.Alpha-fetoprotein-producing rectal cancer successfully responded to preoperative chemoradiotherapy: case report
P2860
Q30235044-8A79627D-C29E-40A1-B9CB-F104AFADF7BAQ33798353-026C109E-752E-4061-A660-F8693C53B31BQ33895624-078B2AA0-49A2-40E0-AE6B-BC9C7D107C3AQ36303649-2A5BA858-0A08-49FC-AD5C-2A3B6C410DF6Q37295422-FA7A874F-F0B6-452C-96E2-1220780D2441Q37707552-F82C826A-1C85-407E-B67D-2F8F0E53685CQ38618772-84B59044-DE8C-4BDA-812C-00F399A5268CQ38650502-B6E52506-A0AD-4516-9134-98B2306FEE97Q40427841-37F1A2EA-0328-4C59-98FC-D87A73530777Q41696556-A7CB1C24-5A19-4D6A-A814-456A4B64D471Q42366884-59171635-9DEB-4993-9FE5-5F43EF95BC8AQ43623679-18D901CA-2A23-4FAE-9E4C-17E339A8E1E7Q46038047-B70B0D51-E68B-4543-9482-2A642EB06BCFQ47718910-D87F24B3-3DF5-4877-850D-BB9CE9BAC6EDQ48308880-5065BC2F-1C18-4CFF-AF91-5E0A7349324DQ49714790-19575EA8-629C-4F91-B7B4-EAB87C9306A5Q53172925-4C034BA6-2E82-4AB6-9A7E-C56A1FE01CD9Q53236215-2F62E28E-3F8F-4E08-BA8C-FC38D2630F78Q55023819-329C040F-E7D4-4910-BF2A-5659732164D5Q55077052-46FBB1DD-6371-49C5-8D63-82EBD7DB9C64Q55127854-DF2BB293-F854-4898-A9B6-6CF0AC1107BFQ55381199-EBAC7B77-3371-41F8-9B14-57E0EE9084F6Q55710885-0748E2A4-FC21-4BFA-8D95-88864C3550DAQ58762057-C5CC8FA8-4CCF-4519-BAB1-4D930536DA00
P2860
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Neoadjuvant 5-FU or Capecitabi ...... III Randomized Clinical Trial
@en
type
label
Neoadjuvant 5-FU or Capecitabi ...... III Randomized Clinical Trial
@en
prefLabel
Neoadjuvant 5-FU or Capecitabi ...... III Randomized Clinical Trial
@en
P2093
P2860
P356
P1476
Neoadjuvant 5-FU or Capecitabi ...... III Randomized Clinical Trial
@en
P2093
Amit Arora
Anthony F Shields
Benjamin T Marchello
Carmen J Allegra
David P Ryan
Dennis F Moore
Gamini Soori
Greg Yothers
Henry C Pitot
Janice F Eakle
P2860
P356
10.1093/JNCI/DJV248
P407
P577
2015-09-14T00:00:00Z